Renata Jaskula-Sztul, Ph.D., University of Wisconsin Medical School (Madison), and colleagues will deliver an oral presentation entitled “Targeted Delivery of a Novel Histone Deacetylase Inhibitor, AB3, Using Unimolecular Micelles to Improve Antitumor Effect in Medullary Thyroid Cancer.” MTC is a neuroendocrine tumor that accounts for 3-5% of thyroid cancers. …
Androgen deprivation therapy (ADT), which reduces levels of male hormones in the body to prevent them from stimulating cancer cells, is a mainstay of treatment for prostate cancer. Despite its anticancer effects, ADT has been associated with heart problems, including increased risk of diabetes, coronary heart disease, heart attacks, and sudden cardiac death. To investigate this potential link thoroughly, Paul Nguyen, MD, of the Dana-Farber/Brigham and Women’s Cancer Center in Boston, along with David Ziehr of Harvard Medical School and their colleagues, analyzed information on 5,077 men with prostate cancer who were treated between 1997 and 2006…
Marie-Elise Parent and Marie-Claude Rousseau, professors at university’s School of Public Health, and their colleague Andrea Spence, published their findings in the journal Cancer Epidemiology. The results were obtained as part of the Montreal study PROtEuS (Prostate Cancer & Environment Study), in which 3,208 men responded to a questionnaire on, amongst other things, their sex lives. Of these men, 1,590 were diagnosed with prostate cancer between September 2005 and August 2009, while 1,618 men were part of the control group. Risk associated with number of partners Overall, men with prostate cancer were twice as likely as others to have a relative with cancer…
Marie-Elise Parent and Marie-Claude Rousseau, professors at university’s School of Public Health, and their colleague Andrea Spence, published their findings in the journal Cancer Epidemiology. The results were obtained as part of the Montreal study PROtEuS (Prostate Cancer & Environment Study), in which 3,208 men responded to a questionnaire on, amongst other things, their sex lives…
The study found that adding tomosynthesis (3D mammography) to routine biennial digital mammography screening among U.S. women with dense breasts could improve health outcomes at a reasonable cost relative to digital mammography screening alone. This is the first comparative effectiveness study performed at the national level using an established model, and it could influence future screening recommendations for women with dense breast tissue who comprise nearly half of all women in the United States. “We felt that this analysis would help inform timely policy and practice decisions given both increased attention to screening for women with dense breasts and rapid adoption of tomosynthesis in routine practice,” said Christoph I. …
The research reveals that women who consume foods containing flavonols and flavanones (both subclasses of dietary flavonoids) significantly decrease their risk of developing epithelial ovarian cancer, the fifth-leading cause of cancer death among women. The research team studied the dietary habits of 171,940 women aged between 25 and 55 for more than three decades. The team found that those who consumed food and drinks high in flavonols (found in tea, red wine, apples and grapes) and flavanones (found in citrus fruit and juices) were less likely to develop the disease. Ovarian cancer affects more than 6,500 women in the UK each year…
But a cunningly simple new device can stop that vital information from “going to waste.” Brigham Young University chemist Adam Woolley and his students made a device that can detect markers of kidney disease and prostate cancer in a few minutes. All you have to do is drop a sample into a tiny tube and see how far it goes…
Reporting in the October 26, 2014 edition of Nature Genetics, investigators from Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard said the mutated gene helps control an important cell-signaling pathway, Wnt, that has been implicated in many forms of cancer. They suggest that the RNF43 mutation may serve as a biomarker that identifies patients with colorectal and endometrial cancer who could benefit from precision cancer drugs that target the Wnt pathway, although no such drugs are currently available. “Tumors that have this mutation may be telling us that they are dependent on the Wnt signaling pathway, and they will be uniquely sensitive to drugs that inhibit this pathway,” said Charles Fuchs, MD, MPH, an author of the paper and director of the Center for Gastrointestinal Cancer at Dana-Farber. He is also affiliated with Brigham and Women’s Hospital and the Harvard School of Public Health…
Researchers at M.D. …
Of course, the effort was hardly so simple as doubling up. …